ライフサイエンスコーパス: PTCA

1 PTCA and CABG, as performed at this institution, posed l

2 PTCA is performed primarily to improve health-related qu

3 PTCA of both iliac arteries of 23 New Zealand White rabb

4 n, 93% had undergone >/=1 CABG, 42% had >/=1 PTCA, 76% were in angina class IV, and 24% were in angin

5 tals (noninvasive 32.5%, cath-capable 31.2%, PTCA-capable 32.9% and CABG-capable 35.9%, p < 0.001 by

6 rate was 2.5% for hospitals performing <200 PTCA procedures per year but only 1.3% for hospitals per

7 s 8.6% for 6668 CABG patients, 6.4% for 4836 PTCA patients, and 4.1% for 4280 stent patients.

8 rdial infarction (MI) occurred in 73 (14.5%) PTCA patients and 63 (12.3%) medical patients (differenc

9 omized to balloon angioplasty (PTCA; n=518), PTCA+abciximab (n=528), stenting (n=512), and stenting+a

10 treated patients (16% with diabetes) and 528 PTCA-treated patients (18% with diabetes).

11 as 2.3% for 909 stent patients, 4.3% for 652 PTCA patients, 9.4% for 288 CAB (IMG-) patients, and 5.0

12 even year survival were 76.4% CABG and 55.7% PTCA (p = 0.0011).

13 cal by assigned treatment (86.4% CABG, 86.8% PTCA, p = 0.72).

14 se survival (+/-SE) was: stent, 82.5+/-2.8%; PTCA, 81.6+/-3.1%; CAB (IMG-), 74.4+/-5.4%; and CAB (IMG

15 cardiac catheterization (OR, 0.03 to 0.85), PTCA (OR, 0.20 to 0.87), and CABG (OR, 0.22 to 0.68).

16 We used perylene tetracarboxylic acid (PTCA) to functionalize the graphene surface and selectiv

17 ion of the pyrrole-2,3,5-tricarboxylic acid (PTCA) derivative of melanin.

18 biomarker pyrrole-2,3,5-tricarboxylic acid (PTCA) was evaluated as a means of normalizing drug respo

19 (PDCA) and pyrrole-2,3,5-tricarboxylic acid (PTCA), markers for DHI and DHICA units, respectively, ar

20 pared in patients achieving an optimal acute PTCA result (residual core laboratory diameter stenosis

21 l atherectomy (RA), both followed by adjunct PTCA; 119 patients (158 ISR lesions) were treated with E

22 After PTCA, there was regional upregulation of integrin alpha(

23 aphic and procedural events during and after PTCA.

24 the risk of in-hospital complications after PTCA or CABG, and no long-term mortality data exist from

25 ibited mural thrombosis for only 1 day after PTCA, whereas ticlopidine treatment alone had no signifi

26 Three days after PTCA, abciximab/ticlopidine treatment decreased mural th

27 Twenty-eight days after PTCA, there was a significant reduction of neointima wit

28 nut oil for 10 days before and 60 days after PTCA.

29 s evaluated by serial echocardiography after PTCA, after AO infusion, at 24 h and at one and three mo

30 Two hours after PTCA, abciximab therapy significantly decreased the numb

31 Six hours after PTCA, obstruction of lumen by thrombus was reduced signi

32 Whether smoking also affects HRQOL after PTCA is currently unknown.

33 laser inhibited neointimal hyperplasia after PTCA in cholesterol-fed rabbits for up to 60 days.

34 Neointimal hyperplasia after PTCA is an important component of restenosis.

35 the site of PTCA reduces luminal loss after PTCA by inhibiting constrictive remodeling.

36 ntagonist of TGF-beta1 on luminal loss after PTCA.

37 any as 50% of patients within 6 months after PTCA in acute myocardial infarction (AMI), which necessi

38 ad undergone CABG, either initially or after PTCA.

39 he ability to predict adverse outcomes after PTCA.

40 d occurred in 20.0 percent of patients after PTCA, 16.5 percent after PTCA plus abciximab, 11.5 perce

41 stablished restenosis was 40.8 percent after PTCA and 22.2 percent after stenting (P<0.001), and the

42 t of patients after PTCA, 16.5 percent after PTCA plus abciximab, 11.5 percent after stenting, and 10

43 ularization (ranging from 15.7 percent after PTCA to 5.2 percent after stenting plus abciximab, P<0.0

44 beta3 inhibits constrictive remodeling after PTCA and reduces luminal loss.

45 delay the process of dissection repair after PTCA.

46 n denuded vessels - predict restenosis after PTCA.

47 ntral to the development of restenosis after PTCA.

48 al or "stent-like" angiographic result after PTCA is associated with favorable clinical outcomes.

49 pulation, HRQOL improved significantly after PTCA for all scales except general health perception, wi

50 dialysis patients in the United States after PTCA, coronary stenting, or CABG.

51 sk adjust mortality and bypass surgery after PTCA.

52 How survival after PTCA and CABG compares in these high-risk anatomic subse

53 rentially influence long-term survival after PTCA or CABG.

54 survival was 87% versus 84% (p = 0.9) in all PTCA and CABG patients (including diabetics) with two-ve

55 survival was 70% versus 74% (p = 0.6) in all PTCA and CABG patients (n = 176), and 82% versus 73% (p

56 ere randomly assigned to undergo PTCA alone, PTCA + abciximab, stenting alone, or stenting + abcixima

57 Among PTCA patients, the mean percentage increase in total jeo

58 , atheroablation was performed in 54.8%, and PTCA alone was performed in 9.8%.

59 Cox regression analysis identified age and PTCA strategy as independent predictors of long-term MAC

60 g 38.5% and 42.7% assigned to PTCA alone and PTCA + abciximab, respectively.

61 rence in five-year survival between CABG and PTCA groups.

62 Early differences between CABG and PTCA in costs and quality of life were no longer signifi

63 d in hospitals that provide on-site CABG and PTCA, income was a significant determinant of procedures

64 s or hospitals that provide on-site CABG and PTCA.

65 hospitals or hospitals that provide CABG and PTCA.

66 for the indirect comparison between DES and PTCA for target lesion or vessel revascularisation was 0

67 in 32.9%, 37.4% and 64.9%, respectively, and PTCA in 0.0%, 5.1% and 31.4%, both p < 0.001 by chi-squa

68 ) compared with coronary artery stenting and PTCA.

69 taneous transluminal coronary angioplasties (PTCAs) are currently performed annually in the United St

70 onary bypass surgery (CABG) and angioplasty (PTCA) have been compared in several randomized trials, b

71 ized to stenting versus balloon angioplasty (PTCA) and abciximab versus no abciximab according to a 2

72 e randomized to undergo balloon angioplasty (PTCA, n=448) or coronary stenting (n=452).

73 nset were randomized to balloon angioplasty (PTCA; n=518), PTCA+abciximab (n=528), stenting (n=512),

74 cutaneous transluminal coronary angioplasty (PTCA) (with or without atherectomy) in the side branch,

75 cutaneous transluminal coronary angioplasty (PTCA) after acute myocardial infarction (AMI) reduces mo

76 cutaneous transluminal coronary angioplasty (PTCA) alone.

77 cutaneous transluminal coronary angioplasty (PTCA) and continued medical treatment.

78 cutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass graft surgery (CABG).

79 cutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG) on long

80 cutaneous transluminal coronary angioplasty (PTCA) and coronary-artery bypass grafting (CABG) on a ni

81 cutaneous transluminal coronary angioplasty (PTCA) capability.

82 cutaneous transluminal coronary angioplasty (PTCA) for acute myocardial infarction (AMI) can be diffi

83 cutaneous transluminal coronary angioplasty (PTCA) for the treatment of coronary artery disease, inco

84 cutaneous transluminal coronary angioplasty (PTCA) in acute myocardial infarction reduces the rates o

85 cutaneous transluminal coronary angioplasty (PTCA) in high-risk anatomic subsets.

86 cutaneous transluminal coronary angioplasty (PTCA) induces thrombus formation and inflammation in the

87 ork State conventional coronary angioplasty (PTCA) model of clinical outcomes to evaluate whether it

88 cutaneous transluminal coronary angioplasty (PTCA) of the culprit artery restored a culprit artery CT

89 cutaneous transluminal coronary angioplasty (PTCA) on health-related quality of life (HRQOL) in patie

90 cutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG), sh

91 cutaneous transluminal coronary angioplasty (PTCA) or coronary artery bypass graft surgery (CABG).

92 cutaneous transluminal coronary angioplasty (PTCA) or for coronary artery bypass graft surgery (CABG)

93 cutaneous transluminal coronary angioplasty (PTCA) procedures performed at hospitals (volume) and in-

94 cutaneous Transluminal Coronary Angioplasty (PTCA) registries.

95 cutaneous transluminal coronary angioplasty (PTCA) strategy.

96 cutaneous transluminal coronary angioplasty (PTCA) versus coronary artery bypass graft surgery (CABG)

97 cutaneous transluminal coronary angioplasty (PTCA) with an optimal or "stent-like" result versus pati

98 cutaneous transluminal coronary angioplasty (PTCA) with thrombolytic therapy for acute ST-segment ele

99 cutaneous transluminal coronary angioplasty (PTCA) with thrombolytic therapy in acute myocardial infa

100 cutaneous transluminal coronary angioplasty (PTCA), abdominal aortic aneurysm (AAA) repair, and carot

101 cutaneous transluminal coronary angioplasty (PTCA), and coronary artery bypass grafting (CABG) were r

102 s transluminal balloon coronary angioplasty (PTCA), bare-metal stents (BMS), and drug-eluting stents

103 cutaneous transluminal coronary angioplasty (PTCA), influences the prognosis in such patients.

104 cutaneous transluminal coronary angioplasty (PTCA).

105 nt of restenosis after coronary angioplasty (PTCA).

106 auses restenosis after coronary angioplasty (PTCA).

107 cutaneous transluminal coronary angioplasty (PTCA).

108 cutaneous transluminal coronary angioplasty (PTCA).

109 cutaneous transluminal coronary angioplasty (PTCA).

110 limit the efficacy of coronary angioplasty (PTCA).

111 cutaneous transluminal coronary angioplasty (PTCA).

112 cutaneous transluminal coronary angioplasty (PTCA).

113 cutaneous transluminal coronary angioplasty (PTCA).

114 th-capable, 25.2%); 3) coronary angioplasty (PTCA-capable, 7.4%); and 4) bypass surgery (CABG-capable

115 ith acute MI undergoing primary angioplasty (PTCA), hyperoxemic blood (pO(2): 600 to 800 mm Hg) was i

116 cutaneous transluminal coronary angioplasty, PTCA) in the treatment of diffuse in-stent restenosis (I

117 cutaneous transluminal coronary angioplasty, PTCA) is unknown.

118 l factors, treatment, and procedures such as PTCA.

119 Among patients assigned PTCA 12.7% subsequently had coronary artery bypass graft

120 t TIMI-3 flow, those with TIMI-3 flow before PTCA had greater left ventricular ejection fraction (57+

121 By multivariate analysis, TIMI-3 flow before PTCA was an independent determinant of survival (odds ra

122 versus medical therapy, revascularization by PTCA and CABG yielded equivalent survival over seven yea

123 ilure with TT, IABP and revascularization by PTCA/CABG was associated with lower in-hospital mortalit

124 we estimated differences in the use of CABG, PTCA, and cardiac catheterization between white versus b

125 At cath-capable, PTCA-capable and CABG-capable hospitals, coronary arteri

126 p < 0.0001) among noninvasive, cath-capable, PTCA-capable and CABG-capable hospitals, respectively.

127 The use of cardiac catheterization, PTCA, CABG, and any revascularization procedure was exam

128 nd adjusted odds ratios for catheterization, PTCA, CABG, and any revascularization procedure were rel

129 andomized trials on 7,964 patients comparing PTCA with CABG.

130 l comparing primary stenting to conventional PTCA for patients with AMI.

131 in 62 670 patients treated with conventional PTCA from 1991 to 1994 to risk adjust mortality and bypa

132 Compared with conventional PTCA, stenting increased procedural costs by approximate

133 th the procedure were more likely to decline PTCA.

134 whom had failed conventional therapy (drugs, PTCA, and/or CABG), were treated with direct myocardial

135 denosine induce PC in the human heart during PTCA.

136 metabolic manifestations of ischemia during PTCA.

137 injuries similar to those that occur during PTCA and related procedures.

138 t may lead to better adjuvant therapy during PTCA.

139 after initial revascularization with either PTCA or CABG was investigated.

140 rmed in 28 patients with 30 lesions (16 ELCA+PTCA, 14 RA+PTCA).

141 e mechanisms of lumen enlargement, both ELCA+PTCA and RA+PTCA can be used to treat diffuse ISR with s

142 nts (158 ISR lesions) were treated with ELCA+PTCA and 130 patients (161 ISR lesions) were treated wit

143 ion revascularization rate was 26% with ELCA+PTCA versus 28% with RA+PTCA (P = NS).

144 is With SeQuent(R) Please Paclitaxel Eluting PTCA Catheter [PEPCAD-DES]; NCT00998439).

145 to one achieved following ROTA and following PTCA (1.70 +/- 0.6 vs. 1.79 +/- 0.5 mm and 1.56 +/- 0.7

146 those with any mental disorder, P = .12 for PTCA and P = .06 for CABG).

147 .4+/-1.4% for CABG patients, 48.2+/-1.5% for PTCA patients, and 48.4+/-2.0% for stent patients (P<0.0

148 rdiac catheterization, from 0.32 to 0.80 for PTCA, and from 0.23 to 0.68 for CABG.

149 population were 84.4% for CABG and 80.9% for PTCA (p = 0.043).

150 s 123,000 dollars versus 120,750 dollars for PTCA, yielding a cost-effectiveness ratio of 14,300 doll

151 ericans were recommended more frequently for PTCA (22 vs. 18%, p = NS), whereas CABG was recommended

152 pared the baseline features and outcomes for PTCA and CABG in the overall registry and its predesigna

153 ere more likely to have a recommendation for PTCA (odds ratio [OR] 1.42, 95% confidence interval [CI]

154 The adjusted relative mortality risk for PTCA in the randomized versus registry population was 1.

155 rly twice as many patients were selected for PTCA (1189) as CABG (625); mortality at 7 years was simi

156 ne differences between patients selected for PTCA versus CABG (adjusted RR, 1.02; P=0.86).

157 (625); mortality at 7 years was similar for PTCA (13.9%) and CABG (14.2%) (P=0.66) before and after

158 Patients considered suitable for PTCA or medical therapy can be safely managed with conti

159 d before the study ended (71 to transfer for PTCA and 67 to thrombolysis).

160 and IABP followed by immediate transfer for PTCA or CABG may be appropriate.

161 ost if the patient had to be transferred for PTCA, and reperfusion was delayed.

162 nts with AMI are more likely to benefit from PTCA or early thrombolysis is not known.

163 Investigation (BARI), 2,108 patients who had PTCA and 1,526 patients who had CABG were evaluated by t

164 Among patients who had PTCA, each unit increase in BMI was associated with a 5.

165 In PTCA patients with multivessel coronary artery disease,

166 as 55.8+/-12.3, compared with 55.7+/-12.7 in PTCA group (n=597, P:=0.82).

167 In the EPILOG trial (Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/

168 2792 patients enrolled in the Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/

169 essel repeat revascularization procedures in PTCA patients during the first six months (16.0% vs. 6.2

170 treatments is then provided, which includes PTCA, directional coronary atherectomy and high speed ro

171 Initial PTCA was successful in 86.9% of lesions and repeat revas

172 ning of jeopardized myocardium after initial PTCA compared with CABG.

173 ularization Investigation to compare initial PTCA versus CABG (n=1829) and who had a reduction in jeo

174 ting at least two of the four interventions (PTCA, BMS, DES, and medical therapy).

175 comparison with women in the 1985-1986 NHLBI PTCA registry, in-hospital death/MI/CABG was lower (6.0%

176 EA (OR, 1.56; 95% CI, 1.07 to 2.27), but not PTCA.

177 revascularization was performed in 48.4% of PTCA patients by one year.

178 Quality-of-life benefits of PTCA are diminished by continued smoking.

179 vessel interventions) from the Evaluation of PTCA to Improve Long-Term Outcome by c7E3 GP IIb/IIIa Re

180 An initial policy of PTCA was associated with improved anginal symptoms and e

181 g those undergoing catheterization, rates of PTCA or CABG for patients with mental disorders were not

182 Regionalization of PTCA would not increase travel distance for most patient

183 iated antagonism of TGF-beta1 at the site of PTCA reduces luminal loss after PTCA by inhibiting const

184 only by intramural injection at the site of PTCA.

185 In RITA-2 an initial strategy of PTCA did not influence the risk of death or MI, but it i

186 se were randomized to an initial strategy of PTCA or CABG between 1988 and 1991.

187 to promote smoking cessation at the time of PTCA may substantially improve the health outcomes of th

188 ontemporary prospective multicenter trial of PTCA in the setting of acute coronary syndromes, there w

189 of Angina (RITA-2) is a randomized trial of PTCA versus conservative (medical) care in 1,018 patient

190 The number of PTCAs performed increased by 49% between 1989 and 1995,

191 However, no data are available on PTCA outcomes with an isosmolar contrast agent.

192 Uniform ultrathin ALD coating on PTCA graphene was achieved over a large area.

193 Optimal PTCA was achieved in 40.7% of patients randomized to bal

194 ng stroke, or TVR) was greater after optimal PTCA than routine stenting (21.9% vs. 13.8%, p < 0.001),

195 days occurred more frequently after optimal PTCA than routine stenting (5.1% vs. 2.3%, p = 0.007).

196 ent is superior or necessary when an optimal PTCA or "stent-like" result is achieved is unknown.

197 restenosis also was more common with optimal PTCA than routine stenting (36.2% vs. 22.2%, p = 0.003).

198 gnificant differences in coronary anatomy or PTCA success rates were found.

199 Patients with early CABG or PTCA (<60 days after MPS) were censored.

200 ned to initial treatment strategy of CABG or PTCA and followed for an average of 7.8 years.

201 sease not amenable to treatment with CABG or PTCA.

202 nded end points (primary end point, CABG, or PTCA).

203 tes in the use of cardiac catheterization or PTCA after the CABG report card was released.

204 In patients undergoing DCA or PTCA of saphenous vein graft narrowings, the relationshi

205 (CAVEAT-II) were randomized to either DCA or PTCA, and data from these trials were analyzed retrospec

206 overall reperfusion (thrombolytic therapy or PTCA).

207 irectly compared DES with medical therapy or PTCA.

208 ovided a significant survival advantage over PTCA at 4 years but not at 6.5 years.

209 solute survival advantage favoring CABG over PTCA for all trials at five years (p < 0.02), but no sig

210 diabetes mellitus, the benefit of CABG over PTCA seen at five years was more pronounced at seven yea

211 rction to undergo PTCA alone (518 patients), PTCA plus abciximab therapy (528), stenting alone with t

212 In a porcine PTCA model, intravenous infusions of the integrin antago

213 and neointimal response to oversize porcine PTCA was investigated by use of a selective alpha(IIb)be

214 Even a post-PTCA diameter stenosis of <20% (realized in 12% of patie

215 triple-vessel disease, Killip class and post-PTCA TIMI flow grade <3.

216 scularization (IR) is the result of both pre-PTCA strategy and initial lesion outcome.

217 Primary PTCA is more effective than thrombolytic therapy for the

218 Primary PTCA was better than thrombolytic therapy at reducing ov

219 Reperfusion success of a primary PTCA strategy in patients with previous CABG, although f

220 an optimal result is achieved after primary PTCA in AMI, early and late outcomes can be further impr

221 ion is safe and well tolerated after primary PTCA.

222 can be detected and quantified after primary PTCA.

223 farction trial (PAMI-2), followed by primary PTCA when appropriate.

224 re randomized to either transfer for primary PTCA or on-site thrombolysis.

225 mproved outcome when transferred for primary PTCA versus on-site thrombolysis; however, this will req

226 not the patient was transferred for primary PTCA.

227 gy of emergent hospital transfer for primary PTCA.

228 s on the relative mortality rates of primary PTCA and stenting.

229 ittle is known about the efficacy of primary PTCA in AMI.

230 nts with ST-segment elevation AMI to primary PTCA (n=3872) or thrombolytic therapy (n=3867).

231 lent outcomes in patients undergoing primary PTCA for acute myocardial infarction, in whom TIMI-3 flo

232 Patients undergoing primary PTCA in whom TIMI-3 flow is present before angioplasty p

233 enrolled in 4 PAMI trials undergoing primary PTCA, spontaneous reperfusion (TIMI-3 flow) was present

234 The results seen with primary PTCA remained better than those seen with thrombolytic t

235 k patients have better outcomes with primary PTCA than with thrombolytic therapy.

236 ear medical care costs compared with primary PTCA.

237 atients with 30 lesions (16 ELCA+PTCA, 14 RA+PTCA).

238 of lumen enlargement, both ELCA+PTCA and RA+PTCA can be used to treat diffuse ISR with similar clini

239 te was 26% with ELCA+PTCA versus 28% with RA+PTCA (P = NS).

240 ients (161 ISR lesions) were treated with RA+PTCA.

241 and 14.5% required additional non-randomized PTCA.

242 , 3610 patients who were eligible to receive PTCA and CABG were revascularized between 1989 and 1992.

243 In a logistic regression, PTCA procedures significantly predicted in-hospital mort

244 BARI physicians were able to select PTCA rather than CABG for 65% of registry patients who u

245 stretch coronary artery injury with standard PTCA balloons and then administered intramural injection

246 of renal transplant recipients after stent, PTCA, or CAB with or without internal mammary grafting (

247 tent patients reported less bodily pain than PTCA patients (p = 0.03).

248 ommon after atheroablation and stenting than PTCA, the rates of Q-wave MI and survival were device-in

249 sociated with better long-term survival than PTCA in treated diabetic patients with multivessel coron

250 py in acute myocardial infarction (AMI) that PTCA results in reduced rates of in-hospital mortality,

251 nd pharmacologic PC exist in humans and that PTCA is a useful clinical setting in which to discern th

252 going stent implantation have suggested that PTCA may no longer be a relevant treatment modality for

253 The PTCA group had substantially higher subsequent revascula

254 n measured EF between the CABG group and the PTCA group within multiple subgroups determined by the p

255 ch that aggregate costs were similar for the PTCA and stent groups (18 690 dollars versus 18 859 doll

256 t associated with five-year mortality in the PTCA group; among the CABG group, adjusted relative risk

257 lasty, including 38.5% and 42.7% assigned to PTCA alone and PTCA + abciximab, respectively.

258 o predict 5-year EF, treatment assignment to PTCA or CABG was not significant (P:=0.95).

259 Patients randomized to PTCA had more repeat revascularizations at all time poin

260 %) were significantly less likely to undergo PTCA (11.8% vs 16.8%; P<.001) or CABG (8.2% vs 12.6%; P<

261 with acute myocardial infarction to undergo PTCA alone (518 patients), PTCA plus abciximab therapy (

262 s with AMI were randomly assigned to undergo PTCA alone, PTCA + abciximab, stenting alone, or stentin

263 catheterization, 74% more likely to undergo PTCA, 48% more likely to undergo CABG, and 76% more like

264 atients with three-vessel disease undergoing PTCA and CABG (n = 754) was 79% versus 84% (p = 0.06), r

265 (P=0.003 and <0.0001 for patients undergoing PTCA and CABG, respectively) and a shorter time to subse

266 ffect of a higher BMI in patients undergoing PTCA and to study the impact of weight reduction on the

267 mortality was higher for patients undergoing PTCA in the randomized trial than in the registry (19.1%

268 le blood samples from 14 patients undergoing PTCA who received abciximab therapy, ticlopidine therapy

269 Among patients undergoing PTCA, patients with CKD had a greater frequency of in-ho

270 In patients undergoing PTCA, smoking has been shown to increase risks of late m

271 lusive thrombus on angiography and underwent PTCA.

272 afts with lesions <80 mm in length underwent PTCA, laser ablation, or rotational atherectomy.

273 saline (n = 9); 10 min later, they underwent PTCA (three 2-min balloon inflations 5 min apart).

274 angina at follow-up than those who underwent PTCA (odds ratio, 1.97; 95 percent confidence interval,

275 and HRQOL among 1432 patients who underwent PTCA as part of 2 multicenter clinical trials.

276 (12.1 minutes faster, P<0.001) or to urgent PTCA (31.2 minutes faster, P<0.001).

277 elative risk of cardiac death or AMI (versus PTCA) was 0.90 (95% CI, 0.69 to 1.17) for stent, 0.80 (9

278 ent, the relative risk (RR) for CABG (versus PTCA) patients was 0.80 (95% CI 0.76 to 0.84, P<0.0001)

279 udy, the other major US trial of CABG versus PTCA, and results of other clinical trials that enrolled

280 In diabetic (versus PTCA) patients, the RR for CABG surgery was 0.81 (95% CI

281 For stent (versus PTCA) patients, the RR was 0.94 (95% CI 0.88 to 0.99, P=

282 cost-effectiveness ratio for stenting versus PTCA was favorable at 11 237 dollars/QALY gained and rem

283 Of 908 patients with indications for which PTCA was rated appropriate (score, 7 to 9), 34 percent w

284 in the registry was equally high (26%) with PTCA or CABG.

285 meta-analyses of trials comparing CABG with PTCA have reported short- and intermediate-term outcomes

286 When used in combination with PTCA, coronary stenting and platelet glycoprotein IIb/II

287 sel revascularisation with BMS compared with PTCA (RR 0.68 [0-60.0.77]) and with DES compared with BM

288 CABG was cost-effective as compared with PTCA for multivessel disease.

289 The C/E ratio for stenting compared with PTCA was $10 550 per repeat revascularization avoided.

290 Our results suggest that, when compared with PTCA, CABG is associated with a lower five-year mortalit

291 Compared with PTCA, stenting increased procedural costs by 1148 dollar

292 uced 1-year TVR and MACE rates compared with PTCA.

293 from 20.4% to 10.8% (P=0.002) compared with PTCA.

294 ease 1-year mortality by >0.2% compared with PTCA.

295 al and angiographic restenosis compared with PTCA.

296 or patients randomized to CABG compared with PTCA.

297 low risk patients who could be managed with PTCA alone.

298 r mortality and cardiac mortality rates with PTCA compared with CABG (relative risk [RR] 1.78 and 2.6

299 $1000/patient higher with stenting than with PTCA ($20 571+/-10 693 versus 19 595+/-10 990, P=0.02).

300 cardiac mortality rates with CABG than with PTCA (RR 4.08, P<0.001).